{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:45:11Z","timestamp":1793411111618,"version":"4.5.0"},"reference-count":158,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"SpringWorks Therapeutics, Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Plexiform neurofibromas (PNs) are a hallmark of neurofibromatosis type 1 (NF1), affecting \u223c50% of individuals with the condition. Originating from Schwann cells and other peripheral nerve sheath components, these tumors can cause significant morbidity, including functional impairment, diminished health-related quality of life, chronic pain, and malignant transformation. Managing NF1-PNs is challenging because of disease variability, differing growth rates, and age-related differences in clinical presentation and treatment tolerability. This review examines current therapeutic strategies, including surgery, medical therapies, and emerging treatments, emphasizing individualized care. Highlighted here is the need for age-specific treatment planning, particularly as disease progression, comorbidities, and side-effect profiles differ between pediatric and adult patients. Optimizing outcomes requires personalized surveillance and coordinated multidisciplinary management across all age groups. While MEK inhibitors (MEKi) provide therapeutic benefit, their long-term efficacy and safety, particularly in pediatric patients who may receive these agents for extended periods, warrant further investigation. Additionally, adult patients face unique comorbidities that may complicate therapy. Superficial PNs and potential MEK inhibitor resistance remain underexplored. Growing interest in combination therapies and adjuvant strategies may improve outcomes. Ongoing research is crucial to personalize treatment regimens, to identify effective combinations, and to refine surveillance protocols, ultimately enhancing long-term quality of life for individuals living with NF1-PN.<\/jats:p>","DOI":"10.1093\/neuonc\/noag023","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T12:41:41Z","timestamp":1769863301000},"page":"847-863","source":"Crossref","is-referenced-by-count":4,"title":["Neurofibromatosis type 1-plexiform neurofibromas: Integrating treatment across pediatric and adult populations"],"prefix":"10.1093","volume":"28","author":[{"given":"Amy E","family":"Armstrong","sequence":"first","affiliation":[{"name":"Division of Pediatric Hematology and Oncology, St. Louis Children\u2019s Hospital, Washington University School of Medicine , St. Louis, Missouri,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea M","family":"Gross","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Cincinnati College of Medicine , Cincinnati, Ohio,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1323-7720","authenticated-orcid":false,"given":"Laura J","family":"Klesse","sequence":"additional","affiliation":[{"name":"University of Texas Southwestern\/Children\u2019s Health , Dallas, Texas,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D","family":"Rhodes","sequence":"additional","affiliation":[{"name":"Indiana University School of Medicine , Indianapolis, Indiana,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4437-5237","authenticated-orcid":false,"given":"Shivani","family":"Ahlawat","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine , Baltimore, Maryland,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7874-5585","authenticated-orcid":false,"given":"Verena","family":"Staedtke","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine , Baltimore, Maryland,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilo A","family":"Molina","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology and Oncology, St. Louis Children\u2019s Hospital, Washington University School of Medicine , St. Louis, Missouri,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1719-0771","authenticated-orcid":false,"given":"Angela C","family":"Hirbe","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, Siteman Cancer Center, Barnes Jewish Hospital, Washington University School of Medicine , St. Louis, MO,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"2026043000073423600_noag023-B1","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1146\/annurev-pathol-011811-132441","article-title":"Pathogenesis of plexiform neurofibroma: tumor-stromal\/hematopoietic interactions in tumor progression","volume":"7","author":"Staser","year":"2012","journal-title":"Annu Rev Pathol"},{"key":"2026043000073423600_noag023-B2","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1093\/neuonc\/noac146","article-title":"Management of neurofibromatosis type 1-associated plexiform neurofibromas","volume":"24","author":"Fisher","year":"2022","journal-title":"Neuro Oncol"},{"key":"2026043000073423600_noag023-B3","doi-asserted-by":"publisher","first-page":"e20190660","DOI":"10.1542\/peds.2019-0660","article-title":"Health supervision for children with neurofibromatosis type 1","volume":"143","author":"Miller","year":"2019","journal-title":"Pediatrics"},{"key":"2026043000073423600_noag023-B4","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jpeds.2011.08.051","article-title":"Pediatric plexiform neurofibromas: impact on morbidity and mortality in neurofibromatosis type 1","volume":"160","author":"Prada","year":"2012","journal-title":"J Pediatr"},{"key":"2026043000073423600_noag023-B5","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1017\/s0317167100004017","article-title":"Neurofibromatosis type 1 in a pediatric population: Ste-Justine\u2019s experience","volume":"32","author":"Boulanger","year":"2005","journal-title":"Can J Neurol Sci"},{"key":"2026043000073423600_noag023-B6","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1136\/jmg.39.5.311","article-title":"Malignant peripheral nerve sheath tumours in neurofibromatosis 1","volume":"39","author":"Evans","year":"2002","journal-title":"J Med Genet"},{"key":"2026043000073423600_noag023-B7","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1007\/s00234-005-0033-4","article-title":"MRI growth patterns of plexiform neurofibromas in patients with neurofibromatosis type 1","volume":"48","author":"Mautner","year":"2006","journal-title":"Neuroradiology"},{"key":"2026043000073423600_noag023-B8","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/1750-1172-7-75","article-title":"Growth dynamics of plexiform neurofibromas: a retrospective cohort study of 201 patients with neurofibromatosis 1","volume":"7","author":"Nguyen","year":"2012","journal-title":"Orphanet J Rare Dis"},{"key":"2026043000073423600_noag023-B9","doi-asserted-by":"publisher","first-page":"e661","DOI":"10.1212\/WNL.0000000000201535","article-title":"Ten-year follow-up of internal neurofibroma growth behavior in adult patients with neurofibromatosis type 1 using whole-body MRI","volume":"100","author":"Ly","year":"2023","journal-title":"Neurology"},{"key":"2026043000073423600_noag023-B10","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/s13023-023-02911-2","article-title":"Incidence and prevalence of neurofibromatosis type 1 and 2: a systematic review and meta-analysis","volume":"18","author":"Lee","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"2026043000073423600_noag023-B11","author":"Children\u2019s Tumor Foundation (CTF)"},{"key":"2026043000073423600_noag023-B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.humpath.2017.05.010","article-title":"Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1-a consensus overview","volume":"67","author":"Miettinen","year":"2017","journal-title":"Hum Pathol"},{"key":"2026043000073423600_noag023-B13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/(SICI)1096-8628(19990326)89:1&lt;31::AID-AJMG7&gt;3.0.CO; 2-W","article-title":"Plexiform neurofibromas","volume":"89","author":"Korf","year":"1999","journal-title":"Am J Med Genet"},{"key":"2026043000073423600_noag023-B14","doi-asserted-by":"publisher","first-page":"e35711","DOI":"10.1371\/journal.pone.0035711","article-title":"Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis","volume":"7","author":"Plotkin","year":"2012","journal-title":"PLoS One"},{"key":"2026043000073423600_noag023-B15","doi-asserted-by":"publisher","first-page":"962","DOI":"10.2214\/ajr.184.3.01840962","article-title":"Superficial neurofibroma: a lesion with unique MRI characteristics in patients with neurofibromatosis type 1","volume":"184","author":"Lim","year":"2005","journal-title":"AJR Am J Roentgenol"},{"key":"2026043000073423600_noag023-B16","doi-asserted-by":"publisher","first-page":"e2589","DOI":"10.1002\/brb3.2589","article-title":"The burden of epilepsy and unmet need in people with focal seizures","volume":"12","author":"Ioannou","year":"2022","journal-title":"Brain Behav"},{"key":"2026043000073423600_noag023-B17","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1038\/s41436-021-01170-5","article-title":"Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation","volume":"23","author":"Legius","year":"2021","journal-title":"Genet Med"},{"key":"2026043000073423600_noag023-B18","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/gim.2018.28","article-title":"Care of adults with neurofibromatosis type 1: a clinical practice resource of the American college of medical genetics and genomics (ACMG)","volume":"20","author":"Stewart","year":"2018","journal-title":"Genet Med"},{"key":"2026043000073423600_noag023-B19","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.3390\/cancers15041077","article-title":"Malignant peripheral nerve sheath tumors: latest concepts in disease pathogenesis and clinical management","volume":"15","author":"Yao","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026043000073423600_noag023-B20","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3171\/2015.12.JNS152443","article-title":"Patterns of recurrence and survival in sporadic, neurofibromatosis type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors","volume":"126","author":"Watson","year":"2017","journal-title":"J Neurosurg"},{"key":"2026043000073423600_noag023-B21","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1093\/neuonc\/noy013","article-title":"The characteristics of 76 atypical neurofibromas as precursors to neurofibromatosis 1 associated malignant peripheral nerve sheath tumors","volume":"20","author":"Higham","year":"2018","journal-title":"Neuro Oncol"},{"key":"2026043000073423600_noag023-B22","doi-asserted-by":"publisher","first-page":"S111","DOI":"10.1212\/WNL.0000000000012437","article-title":"Imaging evaluation of plexiform neurofibromas in neurofibromatosis type 1: a survey-based assessment","volume":"97","author":"Ahlawat","year":"2021","journal-title":"Neurology"},{"key":"2026043000073423600_noag023-B23","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1158\/1078-0432.CCR-17-0589","article-title":"Cancer and Central nervous system tumor surveillance in pediatric neurofibromatosis 1","volume":"23","author":"Evans","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2026043000073423600_noag023-B24","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1215\/15228517-2008-011","article-title":"Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1","volume":"10","author":"Mautner","year":"2008","journal-title":"Neuro Oncol"},{"key":"2026043000073423600_noag023-B25","doi-asserted-by":"publisher","first-page":"101818","DOI":"10.1016\/j.eclinm.2022.101818","article-title":"ERN GENTURIS tumour surveillance guidelines for individuals with neurofibromatosis type 1","volume":"56","author":"Carton","year":"2023","journal-title":"EClinicalMedicine"},{"key":"2026043000073423600_noag023-B26","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1016\/j.jid.2024.01.028","article-title":"Whole-body positron emission tomography with (18)F-fluorodeoxyglucose\/magnetic resonance imaging as a screening tool for the detection of malignant transformation in individuals with neurofibromatosis type 1","volume":"144","author":"Fertitta","year":"2024","journal-title":"J Invest Dermatol"},{"key":"2026043000073423600_noag023-B27","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26733","article-title":"Monitoring of plexiform neurofibroma in children and adolescents with neurofibromatosis type 1 by [(18) F]FDG-PET imaging. Is it of value in asymptomatic patients?","volume":"65","author":"Azizi","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"2026043000073423600_noag023-B28","doi-asserted-by":"publisher","first-page":"e0151809","DOI":"10.1371\/journal.pone.0151809","article-title":"Metabolic tumour burden measured by 18F-FDG PET\/CT predicts malignant transformation in patients with neurofibromatosis type-1","volume":"11","author":"Van Der Gucht","year":"2016","journal-title":"PLoS One"},{"key":"2026043000073423600_noag023-B29","doi-asserted-by":"publisher","first-page":"241","DOI":"10.4103\/wjnm.WJNM_71_17","article-title":"Comparison of hybrid 18F-fluorodeoxyglucose positron emission tomography\/magnetic resonance imaging and positron emission tomography\/computed tomography for evaluation of peripheral nerve sheath tumors in patients with neurofibromatosis type 1","volume":"17","author":"Raad","year":"2018","journal-title":"World J Nucl Med"},{"key":"2026043000073423600_noag023-B30","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/pbc.24212","article-title":"18-fluorodeoxyglucose-positron emission tomography (FDG-PET) evaluation of nodular lesions in patients with neurofibromatosis type 1 and plexiform neurofibromas (PN) or malignant peripheral nerve sheath tumors (MPNST)","volume":"60","author":"Meany","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"2026043000073423600_noag023-B31","doi-asserted-by":"publisher","first-page":"7429697","DOI":"10.1155\/2017\/7429697","article-title":"Malignant peripheral nerve sheath tumors state of the science: leveraging clinical and biological insights into effective therapies","volume":"2017","author":"Kim","year":"2017","journal-title":"Sarcoma"},{"key":"2026043000073423600_noag023-B32","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1093\/neuonc\/noae235","article-title":"Consensus recommendations for an integrated diagnostic approach to peripheral nerve sheath tumors arising in the setting of neurofibromatosis type 1 (NF1)","volume":"27","author":"Lucas","year":"2025","journal-title":"Neuro Oncol"},{"key":"2026043000073423600_noag023-B33","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.jpeds.2011.04.008","article-title":"Plexiform neurofibromas in children with neurofibromatosis type 1: frequency and associated clinical deficits","volume":"159","author":"Nguyen","year":"2011","journal-title":"J Pediatr"},{"key":"2026043000073423600_noag023-B34","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s40487-022-00213-4","article-title":"Clinical characteristics and management of children and adults with neurofibromatosis type 1 and plexiform neurofibromas in Denmark: a nationwide study","volume":"11","author":"Ejerskov","year":"2023","journal-title":"Oncol Ther"},{"key":"2026043000073423600_noag023-B35","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1093\/neuonc\/noaa053","article-title":"Longitudinal evaluation of peripheral nerve sheath tumors in neurofibromatosis type 1: growth analysis of plexiform neurofibromas and distinct nodular lesions","volume":"22","author":"Akshintala","year":"2020","journal-title":"Neuro Oncol"},{"key":"2026043000073423600_noag023-B36","doi-asserted-by":"publisher","first-page":"e0232031","DOI":"10.1371\/journal.pone.0232031","article-title":"The effect of pregnancy on growth-dynamics of neurofibromas in neurofibromatosis type 1","volume":"15","author":"Well","year":"2020","journal-title":"PLoS One"},{"key":"2026043000073423600_noag023-B37","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.jpeds.2013.10.081","article-title":"Puberty and plexiform neurofibroma tumor growth in patients with neurofibromatosis type I","volume":"164","author":"Dagalakis","year":"2014","journal-title":"J Pediatr"},{"key":"2026043000073423600_noag023-B38","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1186\/s13023-024-03420-6","article-title":"Whole-body MRI-based long-term evaluation of pediatric NF1 patients without initial tumor burden with evidence of newly developed peripheral nerve sheath tumors","volume":"19","author":"Schmalhofer","year":"2024","journal-title":"Orphanet J Rare Dis"},{"key":"2026043000073423600_noag023-B39","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/j.ajo.2013.01.011","article-title":"Visual outcomes in children with neurofibromatosis type 1 and orbitotemporal plexiform neurofibromas","volume":"155","author":"Avery","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"2026043000073423600_noag023-B40","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1093\/neuonc\/noy067","article-title":"Association of plexiform neurofibroma volume changes and development of clinical morbidities in neurofibromatosis 1","volume":"20","author":"Gross","year":"2018","journal-title":"Neuro Oncol"},{"key":"2026043000073423600_noag023-B41","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1212\/01.wnl.0000250332.89420.e6","article-title":"NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight","volume":"68","author":"Dombi","year":"2007","journal-title":"Neurology"},{"key":"2026043000073423600_noag023-B42","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1136\/jmg.2008.061051","article-title":"Longitudinal study of neurofibromatosis 1 associated plexiform neurofibromas","volume":"46","author":"Tucker","year":"2009","journal-title":"J Med Genet"},{"key":"2026043000073423600_noag023-B43","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1002\/cncr.22098","article-title":"Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution","volume":"107","author":"Anghileri","year":"2006","journal-title":"Cancer"},{"key":"2026043000073423600_noag023-B44","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1093\/jpepsy\/jsr124","article-title":"Social-emotional functioning of children and adolescents with neurofibromatosis type 1 and plexiform neurofibromas: relationships with cognitive, disease, and environmental variables","volume":"37","author":"Martin","year":"2012","journal-title":"J Pediatr Psychol"},{"key":"2026043000073423600_noag023-B45","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1136\/jmg-2024-110396","article-title":"Six at sixty. Malignant peripheral nerve sheath tumours in NF1: 20-year review of a highly cited paper","volume":"61","author":"Evans","year":"2024","journal-title":"J Med Genet"},{"key":"2026043000073423600_noag023-B46","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s00247-004-1352-z","article-title":"MR imaging of abdominopelvic involvement in neurofibromatosis type 1: a review of 43 patients","volume":"35","author":"Zacharia","year":"2005","journal-title":"Pediatr Radiol"},{"key":"2026043000073423600_noag023-B47","doi-asserted-by":"publisher","first-page":"2752","DOI":"10.1093\/hmg\/ddz095","article-title":"Cdkn2a (Arf) loss drives NF1-associated atypical neurofibroma and malignant transformation","volume":"28","author":"Rhodes","year":"2019","journal-title":"Hum Mol Genet"},{"key":"2026043000073423600_noag023-B48","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1212\/WNL.0000000000002933","article-title":"Sleep and pulmonary outcomes for clinical trials of airway plexiform neurofibromas in NF1","volume":"87","author":"Plotkin","year":"2016","journal-title":"Neurology"},{"key":"2026043000073423600_noag023-B49","doi-asserted-by":"publisher","first-page":"101722","DOI":"10.1016\/j.eucr.2021.101722","article-title":"Pelvic plexiform neurofibroma during bowel\/bladder dysfunction in an NF1 pediatric patient: a case report","volume":"38","author":"Allen","year":"2021","journal-title":"Urol Case Rep"},{"key":"2026043000073423600_noag023-B50","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"2026043000073423600_noag023-B51","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1007\/s00381-022-05513-8","article-title":"Clinical and humanistic burden among pediatric patients with neurofibromatosis type 1 and plexiform neurofibroma in the USA","volume":"38","author":"Yang","year":"2022","journal-title":"Childs Nerv Syst"},{"key":"2026043000073423600_noag023-B52","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/ajmg.a.37987","article-title":"Using a qualitative approach to conceptualize concerns of patients with neurofibromatosis type 1 associated plexiform neurofibromas (pNF) across the lifespan","volume":"173","author":"Lai","year":"2017","journal-title":"Am J Med Genet A"},{"key":"2026043000073423600_noag023-B53","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/hex.13413","article-title":"How do people with neurofibromatosis type 1 (the forgotten victims) live? A grounded theory study","volume":"25","author":"Foji","year":"2022","journal-title":"Health Expect"},{"key":"2026043000073423600_noag023-B54","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2147\/PHMT.S362679","article-title":"Neurofibromatosis type 1 (NF1): addressing the transition from pediatric to adult care","volume":"14","author":"Radtke","year":"2023","journal-title":"Pediatric Health Med Ther"},{"key":"2026043000073423600_noag023-B55","doi-asserted-by":"publisher","first-page":"883019","DOI":"10.3389\/fpsyg.2022.883019","article-title":"Sexual self-esteem and psychological burden of adults with neurofibromatosis type 1","volume":"13","author":"Leidger","year":"2022","journal-title":"Front Psychol"},{"key":"2026043000073423600_noag023-B56","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1177\/17407745231205577","article-title":"Recommendations for assessing appearance concerns related to plexiform and cutaneous neurofibromas in neurofibromatosis 1 clinical trials","volume":"21","author":"Merker","year":"2024","journal-title":"Clin Trials"},{"key":"2026043000073423600_noag023-B57","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1186\/s12885-023-10996-y","article-title":"Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas","volume":"23","author":"Armstrong","year":"2023","journal-title":"BMC Cancer"},{"key":"2026043000073423600_noag023-B58","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13023-020-1310-3","article-title":"Neurofibromatosis 1 French national guidelines based on an extensive literature review since 1966","volume":"15","author":"Bergqvist","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"2026043000073423600_noag023-B59","author":"Howick"},{"key":"2026043000073423600_noag023-B60","author":"Howick"},{"key":"2026043000073423600_noag023-B61","author":"OCEBM Levels of Evidence Working Group"},{"key":"2026043000073423600_noag023-B62","doi-asserted-by":"publisher","first-page":"i134","DOI":"10.1093\/noajnl\/vdaa017","article-title":"Clinical trial design in neurofibromatosis type 1 as a model for other tumor predisposition syndromes","volume":"2","author":"Gross","year":"2020","journal-title":"Neurooncol Adv"},{"key":"2026043000073423600_noag023-B63","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1212\/01.wnl.0000435744.57038.af","article-title":"Recommendations for imaging tumor response in neurofibromatosis clinical trials","volume":"81","author":"Dombi","year":"2013","journal-title":"Neurology"},{"key":"2026043000073423600_noag023-B64","doi-asserted-by":"publisher","first-page":"10503","DOI":"10.1200\/JCO.2018.36.15_suppl.10503","article-title":"SPRINT: phase II study of the MEK 1\/2 inhibitor selumetinib (AZD6244, ARRY-142886) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN)","volume":"36","author":"Gross","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026043000073423600_noag023-B65","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1200\/JCO.24.01034","article-title":"ReNeu: a pivotal, phase IIb trial of mirdametinib in adults and children with symptomatic neurofibromatosis type 1-associated plexiform neurofibroma","volume":"43","author":"Moertel","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026043000073423600_noag023-B66","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.acra.2017.09.004","article-title":"Volumetric MRI analysis of plexiform neurofibromas in neurofibromatosis type 1: comparison of two methods","volume":"25","author":"Cai","year":"2018","journal-title":"Acad Radiol"},{"key":"2026043000073423600_noag023-B67","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1002\/ajmg.a.37123","article-title":"Pain interference in youth with neurofibromatosis type 1 and plexiform neurofibromas and relation to disease severity, social-emotional functioning, and quality of life","volume":"167a","author":"Wolters","year":"2015","journal-title":"Am J Med Genet A"},{"key":"2026043000073423600_noag023-B68","doi-asserted-by":"publisher","first-page":"S50","DOI":"10.1212\/WNL.0000000000012421","article-title":"Current recommendations for patient-reported outcome measures assessing domains of quality of life in neurofibromatosis clinical trials","volume":"97","author":"Wolters","year":"2021","journal-title":"Neurology"},{"key":"2026043000073423600_noag023-B69","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1212\/WNL.0000000000002930","article-title":"Consensus for NF clinical trials","volume":"87","author":"Widemann","year":"2016","journal-title":"Neurology"},{"key":"2026043000073423600_noag023-B70","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/s0022-3476(97)70092-1","article-title":"Prognostic signs in the surgical management of plexiform neurofibroma: the children\u2019s hospital of Philadelphia experience, 1974-1994","volume":"131","author":"Needle","year":"1997","journal-title":"J Pediatr"},{"key":"2026043000073423600_noag023-B71","doi-asserted-by":"publisher","first-page":"e432242","DOI":"10.1200\/EDBK_432242","article-title":"Contemporary approach to neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors","volume":"44","author":"Hirbe","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2026043000073423600_noag023-B72","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/neuonc\/noaa280","article-title":"A Bayesian approach for diagnostic accuracy of malignant peripheral nerve sheath tumors: a systematic review and meta-analysis","volume":"23","author":"Martin","year":"2021","journal-title":"Neuro Oncol"},{"key":"2026043000073423600_noag023-B73","doi-asserted-by":"publisher","first-page":"928","DOI":"10.2214\/AJR.07.2060","article-title":"Value of PET in the assessment of patients with neurofibromatosis type 1","volume":"189","author":"Bredella","year":"2007","journal-title":"AJR Am J Roentgenol"},{"key":"2026043000073423600_noag023-B74","doi-asserted-by":"publisher","first-page":"e0138386","DOI":"10.1371\/journal.pone.0138386","article-title":"Diagnostic accuracy of PET\/CT-guided percutaneous biopsies for malignant peripheral nerve sheath tumors in neurofibromatosis type 1 patients","volume":"10","author":"Brahmi","year":"2015","journal-title":"PLoS One"},{"key":"2026043000073423600_noag023-B75","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1634\/theoncologist.2013-0328","article-title":"Malignant peripheral nerve sheath tumors","volume":"19","author":"Farid","year":"2014","journal-title":"Oncologist"},{"key":"2026043000073423600_noag023-B76","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3390\/children9010038","article-title":"Malignant peripheral nerve sheath tumors-a comprehensive review of pathophysiology, diagnosis, and multidisciplinary management","volume":"9","author":"Knight","year":"2022","journal-title":"Children (Basel)"},{"key":"2026043000073423600_noag023-B77","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.3171\/2019.7.JNS191353","article-title":"Safe marginal resection of atypical neurofibromas in neurofibromatosis type 1","volume":"133","author":"Nelson","year":"2020","journal-title":"J Neurosurg"},{"key":"2026043000073423600_noag023-B78","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1172\/JCI60578","article-title":"MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors","volume":"123","author":"Jessen","year":"2013","journal-title":"J Clin Invest"},{"key":"2026043000073423600_noag023-B79","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","article-title":"Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas","volume":"375","author":"Dombi","year":"2016","journal-title":"N Engl J Med"},{"key":"2026043000073423600_noag023-B80","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1093\/neuonc\/noac109","article-title":"Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity","volume":"24","author":"Gross","year":"2022","journal-title":"Neuro Oncol"},{"key":"2026043000073423600_noag023-B81","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1200\/JCO.20.02220","article-title":"NF106: a neurofibromatosis clinical trials consortium phase II trial of the MEK inhibitor mirdametinib (PD-0325901) in adolescents and adults with NF1-related plexiform neurofibromas","volume":"39","author":"Weiss","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026043000073423600_noag023-B82","doi-asserted-by":"crossref","first-page":"10504","DOI":"10.1200\/JCO.2018.36.15_suppl.10504","article-title":"Trametinib in pediatric patients with neurofibromatosis type 1 (NF-1)-associated plexiform neurofibroma: a phase I\/IIa study [abstract]","volume":"36","author":"McCowage","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026043000073423600_noag023-B83","author":"Reddy","year":"2021"},{"key":"2026043000073423600_noag023-B84","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","article-title":"Selumetinib in children with inoperable plexiform neurofibromas","volume":"382","author":"Gross","year":"2020","journal-title":"N Engl J Med"},{"key":"2026043000073423600_noag023-B85","author":"Viskochil","year":"2024"},{"key":"2026043000073423600_noag023-B86","doi-asserted-by":"publisher","first-page":"956","DOI":"10.3390\/ph15080956","article-title":"Efficacy and safety of trametinib in neurofibromatosis type 1-associated plexiform neurofibroma and low-grade glioma: a systematic review and meta-analysis","volume":"15","author":"Wang","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"2026043000073423600_noag023-B87","doi-asserted-by":"publisher","first-page":"iii420","DOI":"10.1093\/neuonc\/noaa222.619","article-title":"MEK inhibitor binimetinib shows clinical activity in children with neurofibromatosis type 1- associated plexiform neurofibromas: a report from Pnoc and the Nf clinical trials consortium [abstract]","volume":"22","author":"Mueller","year":"2020","journal-title":"Neuro Oncol"},{"key":"2026043000073423600_noag023-B88","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1093\/neuonc\/noad086","article-title":"Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1\/2 trial for inoperable plexiform neurofibromas","volume":"25","author":"Gross","year":"2023","journal-title":"Neuro Oncol"},{"key":"2026043000073423600_noag023-B89","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/s41591-024-03361-4","article-title":"Selumetinib in adults with NF1 and inoperable plexiform neurofibroma: a phase 2 trial","volume":"31","author":"Gross","year":"2025","journal-title":"Nat Med"},{"key":"2026043000073423600_noag023-B90","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1093\/neuonc\/noac165","article-title":"MEK inhibitors for neurofibromatosis type 1 manifestations: clinical evidence and consensus","volume":"24","author":"de Blank","year":"2022","journal-title":"Neuro Oncol"},{"key":"2026043000073423600_noag023-B91","doi-asserted-by":"publisher","first-page":"e1109","DOI":"10.1634\/theoncologist.2020-0069","article-title":"The use of MEK inhibitors in neurofibromatosis type 1-associated tumors and management of toxicities","volume":"25","author":"Klesse","year":"2020","journal-title":"Oncologist"},{"key":"2026043000073423600_noag023-B92","volume-title":"GOMEKLI\u2009TM (Mirdametinib) Capsules, for Oral Use; GOMEKLI\u2009TM (Mirdametinib) Tablets for Oral Suspension [Prescribing Information]","author":"SpringWorks Therapeutics, Inc","year":"2025"},{"key":"2026043000073423600_noag023-B93","author":"Stenger","year":"2020"},{"key":"2026043000073423600_noag023-B94","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41591-020-01193-6","article-title":"Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial","volume":"27","author":"Fisher","year":"2021","journal-title":"Nat Med"},{"key":"2026043000073423600_noag023-B95","author":"Armstrong","year":"2022"},{"key":"2026043000073423600_noag023-B96","volume-title":"KOSELUGO\u00ae (Selumetinib) Capsules; for Oral Use. KOSELUGO\u00ae (Selumetinib) Oral Granules [Prescribing Information]","author":"AstraZeneca Pharmaceuticals LP","year":"2025"},{"key":"2026043000073423600_noag023-B97","author":"AstraZeneca PLC","year":"2025"},{"key":"2026043000073423600_noag023-B98","author":"European Medicines Agency"},{"key":"2026043000073423600_noag023-B99","doi-asserted-by":"publisher","first-page":"3014","DOI":"10.1200\/JCO.2025.43.16_suppl.3014","article-title":"Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibroma (PN): primary analysis of KOMET (NCT04924608), a phase 3, international, randomized, placebo-controlled study [abstract]","volume":"43","author":"Chen","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026043000073423600_noag023-B100","author":"SpringWorks Therapeutics, Inc","year":"2025"},{"key":"2026043000073423600_noag023-B101","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1097\/IAE.0000000000002451","article-title":"Ocular adverse events associated with MEK inhibitors","volume":"39","author":"M\u00e9ndez-Mart\u00ednez","year":"2019","journal-title":"Retina"},{"key":"2026043000073423600_noag023-B102","author":"National Comprehensive Cancer Network","year":"2025"},{"key":"2026043000073423600_noag023-B103","doi-asserted-by":"publisher","first-page":"v2","DOI":"10.1093\/neuonc\/noae144.004","article-title":"PL02.2.A trametinib in neurofibromatosis type 1 related symptomatic plexiform neurofibromas: one-year follow-up of the TRAIN study [abstract]","volume":"26","author":"Noordhoek","year":"2024","journal-title":"Neuro Oncol"},{"key":"2026043000073423600_noag023-B104","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1186\/s12885-019-6442-2","article-title":"A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK\/ERK pathway: TRAM-01","volume":"19","author":"Perreault","year":"2019","journal-title":"BMC Cancer"},{"key":"2026043000073423600_noag023-B105","author":"Dombi"},{"key":"2026043000073423600_noag023-B106","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1172\/JCI85183","article-title":"Cotargeting MNK and MEK kinases induces the regression of NF1-mutant cancers","volume":"126","author":"Lock","year":"2016","journal-title":"J Clin Invest"},{"key":"2026043000073423600_noag023-B107","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/nop\/npae038","article-title":"Consensus recommendations on management of selumetinib-associated adverse events in pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas","volume":"11","author":"Azizi","year":"2024","journal-title":"Neurooncol Pract"},{"key":"2026043000073423600_noag023-B108","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1007\/s40262-023-01293-9","article-title":"Therapeutic drug monitoring of kinase inhibitors in oncology","volume":"62","author":"van der Kleij","year":"2023","journal-title":"Clin Pharmacokinet"},{"key":"2026043000073423600_noag023-B109","author":"Roman","year":"2024"},{"key":"2026043000073423600_noag023-B110","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/S1470-2045(12)70414-X","article-title":"Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial","volume":"13","author":"Robertson","year":"2012","journal-title":"Lancet Oncol"},{"key":"2026043000073423600_noag023-B111","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1016\/j.jaad.2020.07.044","article-title":"Cutaneous reactions in children treated with MEK inhibitors, BRAF inhibitors, or combination therapy: a multicenter study","volume":"84","author":"Boull","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2026043000073423600_noag023-B112","doi-asserted-by":"publisher","first-page":"e27682","DOI":"10.1002\/pbc.27682","article-title":"Cutaneous reactions to targeted therapies in children with CNS tumors: a cross-sectional study","volume":"66","author":"Song","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"2026043000073423600_noag023-B113","doi-asserted-by":"publisher","first-page":"adv00501","DOI":"10.2340\/00015555-3867","article-title":"Cutaneous adverse events to targeted therapies and immuno-therapies in children: a retrospective study of 103 patients from two tertiary haemato-oncology referral centres","volume":"101","author":"Ollech","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"2026043000073423600_noag023-B114","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1159\/000539374","article-title":"Cutaneous reactions in pediatric patients treated with MEK inhibitors: a retrospective single-center study","volume":"240","author":"Friedland","year":"2024","journal-title":"Dermatology"},{"key":"2026043000073423600_noag023-B115","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/pde.14354","article-title":"Adverse cutaneous effects of mitogen-activated protein kinase inhibitors in children","volume":"38","author":"D\u00e1vila Osorio","year":"2021","journal-title":"Pediatr Dermatol"},{"key":"2026043000073423600_noag023-B116","author":"Hirbe","year":"2024"},{"key":"2026043000073423600_noag023-B117","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/pde.15792","article-title":"Cutaneous toxicities of MEK inhibitor use in children: a comparison of binimetinib and selumetinib","volume":"42","author":"Needle","year":"2025","journal-title":"Pediatr Dermatol"},{"key":"2026043000073423600_noag023-B118","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1111\/jocd.15704","article-title":"Acneiform eruption induced by molecularly targeted agents in antineoplastic therapy: a review","volume":"22","author":"Yuan","year":"2023","journal-title":"J Cosmet Dermatol"},{"key":"2026043000073423600_noag023-B119","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaccao.2022.01.096","article-title":"Mechanistic and clinical overview cardiovascular toxicity of BRAF and MEK\u00a0inhibitors: JACC: CardioOncology state-of-the-art review","volume":"4","author":"Glen","year":"2022","journal-title":"JACC CardioOncol"},{"key":"2026043000073423600_noag023-B120","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.jaccao.2024.07.004","article-title":"Cardiac dysfunction in children and young adults treated with MEK inhibitors: a retrospective, single-center study","volume":"6","author":"Bender","year":"2024","journal-title":"JACC CardioOncol"},{"key":"2026043000073423600_noag023-B121","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S1470-2045(19)30277-3","article-title":"Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial","volume":"20","author":"Fangusaro","year":"2019","journal-title":"Lancet Oncol"},{"key":"2026043000073423600_noag023-B122","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S1470-2045(12)70269-3","article-title":"Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial","volume":"13","author":"Falchook","year":"2012","journal-title":"Lancet Oncol"},{"key":"2026043000073423600_noag023-B123","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s12012-017-9425-z","article-title":"Cardiovascular effects of the MEK inhibitor, trametinib: a case report, literature review, and consideration of mechanism","volume":"17","author":"Banks","year":"2017","journal-title":"Cardiovasc Toxicol"},{"key":"2026043000073423600_noag023-B124","doi-asserted-by":"publisher","first-page":"e381","DOI":"10.1097\/MPH.0000000000000364","article-title":"Trametinib-induced left ventricular dysfunction in a child with relapsed neuroblastoma","volume":"37","author":"Modak","year":"2015","journal-title":"J Pediatr Hematol Oncol"},{"key":"2026043000073423600_noag023-B125","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1093\/annonc\/mdw100","article-title":"Ocular toxicities of MEK inhibitors and other targeted therapies","volume":"27","author":"Stjepanovic","year":"2016","journal-title":"Ann Oncol"},{"key":"2026043000073423600_noag023-B126","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ejca.2016.06.018","article-title":"MEK inhibitor-associated retinopathy (MEKAR) in metastatic melanoma: long-term ophthalmic effects","volume":"65","author":"Urner-Bloch","year":"2016","journal-title":"Eur J Cancer"},{"key":"2026043000073423600_noag023-B127","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/eye.2015.82","article-title":"MEK inhibitors: a new class of chemotherapeutic agents with ocular toxicity","volume":"29","author":"Duncan","year":"2015","journal-title":"Eye (Lond)"},{"key":"2026043000073423600_noag023-B128","doi-asserted-by":"publisher","first-page":"104178","DOI":"10.1016\/j.jaapos.2025.104178","article-title":"Pediatric MEK inhibitor-associated retinopathy: 8-year experience at a tertiary academic center and report of 2 cases","volume":"29","author":"Liu","year":"2025","journal-title":"J AAPOS"},{"key":"2026043000073423600_noag023-B129","doi-asserted-by":"publisher","first-page":"104157","DOI":"10.1016\/j.jaapos.2025.104157","article-title":"Baseline ophthalmic findings and complications in pediatric patients treated with MEK inhibitors","volume":"29","author":"Hazariwala","year":"2025","journal-title":"J AAPOS"},{"key":"2026043000073423600_noag023-B130","doi-asserted-by":"publisher","first-page":"e616","DOI":"10.1093\/oncolo\/oyae014","article-title":"Ocular effects of MEK inhibitor therapy: literature review, clinical presentation, and best practices for mitigation","volume":"29","author":"Jeng-Miller","year":"2024","journal-title":"Oncologist"},{"key":"2026043000073423600_noag023-B131","volume-title":"KOSELUGO\u2122 (Selumetinib) Capsules, for Oral Use [Prescribing Information]","author":"AstraZeneca Pharmaceuticals LP","year":"2024"},{"key":"2026043000073423600_noag023-B132","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.ejca.2017.11.027","article-title":"On\/off dropped head syndrome: a severe adverse event after prolonged treatment with MEK inhibitor","volume":"91","author":"Longvert","year":"2018","journal-title":"Eur J Cancer"},{"key":"2026043000073423600_noag023-B133","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1212\/WNL.0b013e318271f87e","article-title":"Dropped head syndrome: report of three cases during treatment with a MEK inhibitor","volume":"79","author":"Chen","year":"2012","journal-title":"Neurology"},{"key":"2026043000073423600_noag023-B134","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/ced.13297","article-title":"Dropped-head syndrome in a patient under treatment with the MEK inhibitor trametinib for NRAS-mutated metastatic melanoma","volume":"43","author":"Kleemann","year":"2018","journal-title":"Clin Exp Dermatol"},{"key":"2026043000073423600_noag023-B135","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1093\/neuonc\/noae121","article-title":"Safety and efficacy of selumetinib in pediatric and adult patients with neurofibromatosis type 1 and plexiform neurofibroma","volume":"26","author":"Kim","year":"2024","journal-title":"Neuro Oncol"},{"key":"2026043000073423600_noag023-B136","doi-asserted-by":"publisher","first-page":"e550","DOI":"10.1097\/MPH.0000000000001859","article-title":"Trametinib-associated hyponatremia in a child with low-grade glioma is not seen following treatment with alternative MEK inhibitor","volume":"43","author":"Lazow","year":"2021","journal-title":"J Pediatr Hematol Oncol"},{"key":"2026043000073423600_noag023-B137","volume-title":"CABOMETYX\u00ae (Cabozantinib) Tablets, for Oral Use [Prescribing Information]","author":"Exelixis, Inc","year":"2023"},{"key":"2026043000073423600_noag023-B138","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1186\/s12883-023-03429-7","article-title":"Impact of neurofibromatosis type 1 with plexiform neurofibromas on the health-related quality of life and work productivity of adult patients and caregivers in the UK: a cross-sectional survey","volume":"23","author":"Yoo","year":"2023","journal-title":"BMC Neurol"},{"key":"2026043000073423600_noag023-B139","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2147\/AHMT.S303456","article-title":"Natural history and disease burden of neurofibromatosis type 1 with plexiform neurofibromas: a systematic literature review","volume":"12","author":"Copley-Merriman","year":"2021","journal-title":"Adolesc Health Med Ther"},{"key":"2026043000073423600_noag023-B140","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12955-017-0607-y","article-title":"Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the impact of NF1 on quality of life (INF1-QOL) questionnaire","volume":"15","author":"Ferner","year":"2017","journal-title":"Health Qual Life Outcomes"},{"key":"2026043000073423600_noag023-B141","doi-asserted-by":"publisher","DOI":"10.1177\/2050312119829680","article-title":"A qualitative study of the impact of plexiform neurofibromas on need fulfilment in adults with neurofibromatosis type 1","volume":"7","author":"Heaney","year":"2019","journal-title":"SAGE Open Med"},{"key":"2026043000073423600_noag023-B142","doi-asserted-by":"publisher","first-page":"114413","DOI":"10.1016\/j.jpeds.2024.114413","article-title":"Early young adult death underscores the need for adolescent and young adult transition programs in neurofibromatosis type 1","volume":"277","author":"Tarnawsky","year":"2025","journal-title":"J Pediatr"},{"key":"2026043000073423600_noag023-B143","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s12307-012-0115-x","article-title":"The plexiform neurofibroma microenvironment","volume":"5","author":"Yang","year":"2012","journal-title":"Cancer Microenviron"},{"key":"2026043000073423600_noag023-B144","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.eplepsyres.2009.08.001","article-title":"The long-term retention of pregabalin in a large cohort of patients with epilepsy at a tertiary referral centre","volume":"87","author":"Yuen","year":"2009","journal-title":"Epilepsy Res"},{"key":"2026043000073423600_noag023-B145","author":"Bischoff","year":"2025"},{"key":"2026043000073423600_noag023-B146","doi-asserted-by":"publisher","first-page":"e1003734","DOI":"10.1371\/journal.pmed.1003734","article-title":"Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: a cross-sectional study","volume":"18","author":"Szymanski","year":"2021","journal-title":"PLoS Med"},{"key":"2026043000073423600_noag023-B147","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1158\/1078-0432.CCR-24-0797","article-title":"Early detection of malignant and premalignant peripheral nerve tumors using cell-free DNA fragmentomics","volume":"30","author":"Sundby","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026043000073423600_noag023-B148","doi-asserted-by":"publisher","first-page":"e74238","DOI":"10.7554\/eLife.74238","article-title":"Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma","volume":"11","author":"Mattox","year":"2022","journal-title":"eLife."},{"key":"2026043000073423600_noag023-B149","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ejca.2019.10.014","article-title":"A nationwide cohort study on treatment and survival in patients with malignant peripheral nerve sheath tumours","volume":"124","author":"Martin","year":"2020","journal-title":"Eur J Cancer"},{"key":"2026043000073423600_noag023-B150","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/S1470-2045(17)30334-0","article-title":"Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial","volume":"18","author":"Gronchi","year":"2017","journal-title":"Lancet Oncol"},{"key":"2026043000073423600_noag023-B151","doi-asserted-by":"publisher","first-page":"8685638","DOI":"10.1155\/2017\/8685638","article-title":"SARC006: phase II trial of chemotherapy in sporadic and neurofibromatosis type 1 associated chemotherapy-naive malignant peripheral nerve sheath tumors","volume":"2017","author":"Higham","year":"2017","journal-title":"Sarcoma"},{"key":"2026043000073423600_noag023-B152","doi-asserted-by":"publisher","first-page":"3761292","DOI":"10.1155\/2017\/3761292","article-title":"Neoadjuvant ifosfamide and epirubicin in the treatment of malignant peripheral nerve sheath tumors","volume":"2017","author":"Hirbe","year":"2017","journal-title":"Sarcoma"},{"key":"2026043000073423600_noag023-B153","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/S1470-2045(12)70346-7","article-title":"Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial","volume":"13","author":"Woll","year":"2012","journal-title":"Lancet Oncol"},{"key":"2026043000073423600_noag023-B154","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ejca.2018.12.009","article-title":"The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial","volume":"109","author":"Pasquali","year":"2019","journal-title":"Eur J Cancer"},{"key":"2026043000073423600_noag023-B155","doi-asserted-by":"publisher","first-page":"3438","DOI":"10.1158\/1078-0432.CCR-22-2854","article-title":"Combined CDK4\/6 and ERK1\/2 inhibition enhances antitumor activity in NF1-associated plexiform neurofibroma","volume":"29","author":"Flint","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026043000073423600_noag023-B156","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1007\/s11912-024-01527-4","article-title":"Past, present, and future therapeutic strategies for NF-1-associated tumors","volume":"26","author":"Na","year":"2024","journal-title":"Curr Oncol Rep"},{"key":"2026043000073423600_noag023-B157","author":"Saveljeva","year":"2024"},{"key":"2026043000073423600_noag023-B158","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/S1470-2045(24)00202-X","article-title":"Irinotecan and temozolomide in combination with dasatinib and rapamycin versus irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma (RIST-rNB-2011): a multicentre, open-label, randomised, controlled, phase 2 trial","volume":"25","author":"Corbacioglu","year":"2024","journal-title":"Lancet Oncol"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noag023\/66792415\/noag023.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/28\/4\/847\/66792415\/noag023.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/28\/4\/847\/66792415\/noag023.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T04:07:43Z","timestamp":1777522063000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/28\/4\/847\/8466018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":158,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,2,5]]},"published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noag023","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2026,2,5]]}}}